ReNeuron Group (AIM:RENE) has inked a research evaluation agreement with an unnamed ‘major’ US biotech firm to collaborate on a technology that can deliver gene silencing therapeutics.
The research collaboration will focus on the use of ReNeuron's human neural stem cell (hNSC) derived exosomes to deliver the US firm’s ‘neuroscience therapeutic candidates.’
ReNeuron’s developed hNSC stem cells have a natural ability to cross the blood brain barrier and can thus be used to deliver therapeutics for diseases of the brain, the group detailed.
The group will be responsible for manufacturing the exosomes and then loading them with the gene silencing sequences after which the US firm will evaluate the loaded exosomes.
Shares in ReNeuron Group were trading 1.89% higher at 135p on Thursday morning.
If the combination brings positive results, the two parties will jointly create and own a novel therapeutic candidate for future development.
The cell-based therapeutics specialist has described the research evaluation agreement as in line with its strategy of partnering its exosome technology as a novel delivery vehicle.
“This latest exosome collaboration follows our strategy of collaborating and out-licensing our proprietary exosome technology as a novel delivery vector and underlines the potential commercial value of these proprietary nanoparticles,” said Olav Hellebø, CEO of ReNeuron.
Follow News & Updates from ReNeuron Group here: